Literature DB >> 16788244

Non classical HLA genes and non-HLA genes in a population of infants at familial risk of atopy.

A De Silvestri1, C Belloni, M De Amici, P Mazzola, M Zorzetto, M Martinetti, L Salvaneschi, M Cuccia.   

Abstract

AIM: We investigated on parental history and IgE serum level in 2588 consecutive newborns to individuate babies "at risk" of atopy at birth and we analysed the polymorphisms of class III region to evaluate the association with immunogenetic markers of HLA: C4A, C4B, LTA, RAGE and TNFA genes; we performed TNF and IgE receptor (FCERB1) physiologically related gene polymorphisms. RESULT: 791 babies/2588 (30.6%) were considered "at risk" for atopy and followed-up: 400 had familial history of atopy (at least one parent or sibling), 256 had IgE >0.35 kUA/l at birth and during the follow-up and 135 were positive for both conditions. The allele C4B2 was significantly more frequent in the sample of babies at risk (22.1% vs 10%, p< 0.001). Furthermore, the mean value of IgE at birth in babies carrying the allele C4B2 was 2.26 KUA/l versus 0.74 KUA/l in those not carrying this allele (p=0.01). No significant association emerged for RAGE at the centromeric end of class III region and for LTA, TNFA at the telomeric one. TNFRI, TNFRII and FCERB1 gene polymorphisms also seemed not implicated.
CONCLUSION: Our study confirms that HLA class III region seems involved in familial predisposition to atopy, and C4B gene probably acts as a marker of a more restricted subregion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16788244      PMCID: PMC3851371          DOI: 10.1155/2006/321798

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  1 in total

1.  Downregulation of the human peripheral myelin protein 22 gene by miR-29a in cellular models of Charcot-Marie-Tooth disease.

Authors:  Jacquelyn Serfecz; Hannah Bazick; Mohammed Omar Al Salihi; Peter Turner; Christopher Fields; Pedro Cruz; Rolf Renne; Lucia Notterpek
Journal:  Gene Ther       Date:  2019-08-27       Impact factor: 5.250

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.